Five decades of research, peer-reviewed clinical data, and 3D imaging studies all point to the same conclusion: this copper peptide produces real, measurable, compounding improvement in skin quality with consistent use
Phase 2 data published in June showed that once-weekly CagriSema led to an average 15.6% bodyweight reduction at week 32 among type 2 diabetes patients living with overweight or obesity
Requirements specific to the bariatric surgeon who will perform your procedure
It can cross the blood-brain barrier and has been shown to be absorbed from the gut in experimental settings
Phase 3 TRIUMPH trial dose schedule updates The phase 3 TRIUMPH program expanded on the phase 2 dosing framework, and the recent results add important context to how dose schedules may evolve
Current research is exploring: Synergistic combinations of Epitalon with senolytics or gene therapies Advanced delivery systems , such as liposomal encapsulation or transdermal patches Its use in neurodegenerative conditions , including Alzheimers and Parkinsons disease Its effects on immune modulation and systemic inflammation Broader Applications Beyond Anti-Aging Epitalons benefits may go far beyond aging
